Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MCS110 |
| Trade Name | |
| Synonyms | Lacnotuzumab |
| Drug Descriptions |
Lacnotuzumab (MCS110) is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2). |
| DrugClasses | CSF1 Antibody 2 |
| CAS Registry Number | 1831128-32-5 |
| NCIT ID | C80044 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel | Cyclophosphamide Doxorubicin MCS110 Paclitaxel | 0 | 1 |
| Dabrafenib + MCS110 + Trametinib | Dabrafenib MCS110 Trametinib | 0 | 1 |
| Ieramilimab + MCS110 + Spartalizumab | Ieramilimab MCS110 Spartalizumab | 0 | 1 |
| MCS110 | MCS110 | 0 | 2 |
| MCS110 + Spartalizumab | MCS110 Spartalizumab | 0 | 1 |